556 related articles for article (PubMed ID: 10623687)
1. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
Bacci G; Ferrari S; Bertoni F; Rimondini S; Longhi A; Bacchini P; Forni C; Manfrini M; Donati D; Picci P
J Clin Oncol; 2000 Jan; 18(1):4-11. PubMed ID: 10623687
[TBL] [Abstract][Full Text] [Related]
2. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
Tural D; Molinas Mandel N; Dervisoglu S; Oner Dincbas F; Koca S; Colpan Oksuz D; Kantarci F; Turna H; Selcukbiricik F; Hiz M
Jpn J Clin Oncol; 2012 May; 42(5):420-6. PubMed ID: 22416252
[TBL] [Abstract][Full Text] [Related]
3. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli.
Bacci G; Ferrari S; Bertoni F; Donati D; Bacchini P; Longhi A; Brach Del Prever A; Forni C; Rimondini S
J Clin Oncol; 2000 Feb; 18(4):885-92. PubMed ID: 10673532
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.
Bacci G; Picci P; Mercuri M; Ferrari S; Longhi A; Cesari M; Rosito P; Mancini AF; Barbieri E; Baldini N
Acta Oncol; 1998; 37(7-8):671-6. PubMed ID: 10050985
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
7. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
Bacci G; Picci P; Ruggieri P; Ferrari S; Mercuri M; Fabbri N; Rosito P; Barbieri E; Ferraro A; Casadei R
J Chemother; 1993 Aug; 5(4):247-57. PubMed ID: 8229153
[TBL] [Abstract][Full Text] [Related]
8. Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment.
Argon A; Basaran M; Yaman F; Dizdar Y; Sakar B; Camlica H; Bavbek SE; Ozger H; Darendeliler E; Onat H
Jpn J Clin Oncol; 2004 Nov; 34(11):667-72. PubMed ID: 15613556
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
[TBL] [Abstract][Full Text] [Related]
10. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
Paulussen M; Ahrens S; Dunst J; Winkelmann W; Exner GU; Kotz R; Amann G; Dockhorn-Dworniczak B; Harms D; Müller-Weihrich S; Welte K; Kornhuber B; Janka-Schaub G; Göbel U; Treuner J; Voûte PA; Zoubek A; Gadner H; Jürgens H
J Clin Oncol; 2001 Mar; 19(6):1818-29. PubMed ID: 11251014
[TBL] [Abstract][Full Text] [Related]
11. [The type of local treatment conditions the prognosis in patients with nonmetastatic Ewing's sarcoma of the extremities treated with adjuvant chemotherapy].
Bacci G; Ferrari S; Rosito P; Barbieri E; Mercuri M; Iantorno D; Brach Del Prever A; Ruggieri P; Forni C
Minerva Chir; 1997 Apr; 52(4):415-26. PubMed ID: 9265127
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998.
Bacci G; Longhi A; Ferrari S; Mercuri M; Versari M; Bertoni F
Acta Oncol; 2006; 45(4):469-75. PubMed ID: 16760184
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
Meyer WH; Kun L; Marina N; Roberson P; Parham D; Rao B; Fletcher B; Pratt CB
J Clin Oncol; 1992 Nov; 10(11):1737-42. PubMed ID: 1403056
[TBL] [Abstract][Full Text] [Related]
15. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party.
Craft AW; Cotterill SJ; Bullimore JA; Pearson D
Eur J Cancer; 1997 Jun; 33(7):1061-9. PubMed ID: 9376188
[TBL] [Abstract][Full Text] [Related]
16. [Primitive cutaneous Ewing's sarcoma: a diagnostic and therapeutic dilemma].
Delaplace M; Mélard P; Perrinaud A; Goré C; Vergier B; Machet L
Ann Dermatol Venereol; 2011 May; 138(5):395-8. PubMed ID: 21570564
[TBL] [Abstract][Full Text] [Related]
17. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
Yock TI; Krailo M; Fryer CJ; Donaldson SS; Miser JS; Chen Z; Bernstein M; Laurie F; Gebhardt MC; Grier HE; Tarbell NJ;
J Clin Oncol; 2006 Aug; 24(24):3838-43. PubMed ID: 16921035
[TBL] [Abstract][Full Text] [Related]
18. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
Kushner BH; Meyers PA
J Clin Oncol; 2001 Feb; 19(3):870-80. PubMed ID: 11157041
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
Craft A; Cotterill S; Malcolm A; Spooner D; Grimer R; Souhami R; Imeson J; Lewis I
J Clin Oncol; 1998 Nov; 16(11):3628-33. PubMed ID: 9817284
[TBL] [Abstract][Full Text] [Related]
20. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
